<DOC>
	<DOCNO>NCT02867605</DOCNO>
	<brief_summary>The purpose study evaluate whether oral HA35 supplementation change normal intestinal bacteria , increase intestinal protection , decrease intestinal inflammation permeability , assess health benefit confirm safety profile HA35 .</brief_summary>
	<brief_title>Human Pilot Study - HA35 Dietary Supplement Promoting Intestinal Health</brief_title>
	<detailed_description />
	<criteria>BMI 1925 ( lean ) , BMI 3035 ( obese ) Age 1845 year old Willingness take oral supplement adhere study requirement Diabetes Oral antibiotic within 4 week study initiation History cardiac disease , medication cardiac disease Use statins antihypertensive drug Inflammatory bowel disease include irritable bowel syndrome History intestinal surgery , exclude hernia repair appendectomy Active cancer diagnosis ( except skin cancer ) Chronic acid suppression treatment ( proton pump inhibitor , histamine H2 receptor antagonist ) Immune modulatory treatment ( e.g . chronic immunosuppressive medication , chronic NSAIDs ) Vegetarian vegan diet7 Abnormal liver kidney function measure routine serum chemistry test Severe anemia significant white blood cell platelet abnormalities No additional blood blood product donation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>